IDXX vs NVCT · P/E 40, rev $2.36B vs $304.5M cap
IDEXX Laboratories Inc (IDXX) versus Nuvectis Pharma Inc (NVCT) — a side-by-side from cached financials, not a winner call.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Nuvectis Pharma Inc (NVCT) is a biotechnology company listed on NASDAQ.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
NVCT does not have a complete income-statement cache yet.
IDXX currently screens at market cap $43.08B and trailing P/E 40.2. NVCT currently screens at market cap $304.5M.
Not investment advice. Open the IDXX and NVCT stock pages for the full models.
Not investment advice.